Bone Biologics Corp

Item 1. Business Company Overview We are a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human protein known as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that provides target specific control over bone regeneration. The NELL-1 technology platform has been licensed exclusively for worldwide applications to us through a technology transfer from the UCLA Technology Development Group on behalf of UC Regents (“UCLA TDG”). UCLA TDG and the Company received guidance from the U.S. Food and Drug Administration (“FDA”) that NELL-1/DBM will be classified as a device/drug…

AI summary unavailable — showing raw filing excerpt

Item 1A. Risk Factors The following factors, as well as factors described elsewhere in this Form 10-K, or in other filings by us with the Securities and Exchange Commission (the “SEC”), could adversely affect our consolidated financial position, results of operations or cash flows. Other factors not presently known to us or that we presently believe are not material could also affect our business operations and financial results. Risk Factor Summary The following is a summary of the principal risks that could materially adversely affect our business operations, industry and financial results. ● Risks Related to Our Financial Position and Capital Needs ○ We have a limited operating history.…

AI summary unavailable — showing raw filing excerpt